S&P 500   4,532.76
DOW   35,028.65
QQQ   366.48
S&P 500   4,532.76
DOW   35,028.65
QQQ   366.48
S&P 500   4,532.76
DOW   35,028.65
QQQ   366.48
S&P 500   4,532.76
DOW   35,028.65
QQQ   366.48

Tempest Therapeutics Stock Forecast, Price & News

+0.34 (+9.52%)
(As of 01/19/2022 04:00 PM ET)
Today's Range
50-Day Range
52-Week Range
23,726 shs
Average Volume
24,644 shs
Market Capitalization
$27.02 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive TPST News and Ratings via Email

Sign-up to receive the latest news and ratings for Tempest Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Tempest Therapeutics logo

About Tempest Therapeutics

Tempest Therapeutics, Inc.is a clinical-stage biotechnology company. It develops small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. The company is headquartered in South San Francisco, CA.


Tempest to Present at Upcoming Investor Conferences
September 9, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
Book Value
$26.61 per share


Net Income
$-36.41 million
Pretax Margin




Free Float
Market Cap
$27.02 million
Not Optionable

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End


Overall MarketRank

2.14 out of 5 stars

Medical Sector

478th out of 1,415 stocks

Pharmaceutical Preparations Industry

226th out of 682 stocks

Analyst Opinion: 3.5Community Rank: 4.3Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.3 5 -4 -3 -2 -1 -

Tempest Therapeutics (NASDAQ:TPST) Frequently Asked Questions

Is Tempest Therapeutics a buy right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Tempest Therapeutics in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Tempest Therapeutics stock.
View analyst ratings for Tempest Therapeutics
or view top-rated stocks.

How has Tempest Therapeutics' stock been impacted by Coronavirus?

Tempest Therapeutics' stock was trading at $98.70 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, TPST stock has decreased by 96.0% and is now trading at $3.91.
View which stocks have been most impacted by COVID-19

Are investors shorting Tempest Therapeutics?

Tempest Therapeutics saw a decline in short interest in the month of December. As of December 15th, there was short interest totaling 29,900 shares, a decline of 19.2% from the November 30th total of 37,000 shares. Based on an average trading volume of 17,900 shares, the days-to-cover ratio is currently 1.7 days. Currently, 0.6% of the company's shares are short sold.
View Tempest Therapeutics' Short Interest

When is Tempest Therapeutics' next earnings date?

Tempest Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, February 9th 2022.
View our earnings forecast for Tempest Therapeutics

How were Tempest Therapeutics' earnings last quarter?

Tempest Therapeutics, Inc. (NASDAQ:TPST) announced its quarterly earnings results on Wednesday, November, 10th. The company reported ($1.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.05) by $0.16.
View Tempest Therapeutics' earnings history

When did Tempest Therapeutics' stock split? How did Tempest Therapeutics' stock split work?

Tempest Therapeutics's stock reverse split on Friday, June 25th 2021. The 1-15 reverse split was announced on Friday, June 25th 2021. The number of shares owned by shareholders was adjusted after the market closes on Monday, June 28th 2021. An investor that had 100 shares of Tempest Therapeutics stock prior to the reverse split would have 7 shares after the split.

What price target have analysts set for TPST?

3 equities research analysts have issued 1 year price objectives for Tempest Therapeutics' stock. Their forecasts range from $23.00 to $51.00. On average, they anticipate Tempest Therapeutics' stock price to reach $37.00 in the next year. This suggests a possible upside of 846.3% from the stock's current price.
View analysts' price targets for Tempest Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Tempest Therapeutics' key executives?

Tempest Therapeutics' management team includes the following people:
  • Stephen R. Brady, Chief Executive Officer & Director
  • Thomas W. Dubensky, President & Director
  • Nicholas Maestas, Chief Financial Officer, VP-Strategy & Finance
  • Sam Whiting, Chief Medical Officer & Executive Vice President
  • Chan Whiting, Senior Vice President-Research & Development

What is Tempest Therapeutics' stock symbol?

Tempest Therapeutics trades on the NASDAQ under the ticker symbol "TPST."

How do I buy shares of Tempest Therapeutics?

Shares of TPST can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Tempest Therapeutics' stock price today?

One share of TPST stock can currently be purchased for approximately $3.91.

How much money does Tempest Therapeutics make?

Tempest Therapeutics has a market capitalization of $27.02 million.

How many employees does Tempest Therapeutics have?

Tempest Therapeutics employs 13 workers across the globe.

What is Tempest Therapeutics' official website?

The official website for Tempest Therapeutics is www.millendo.com.

Where are Tempest Therapeutics' headquarters?

Tempest Therapeutics is headquartered at 110 MILLER AVENUE SUITE 100, ANN ARBOR MI, 48104.

How can I contact Tempest Therapeutics?

Tempest Therapeutics' mailing address is 110 MILLER AVENUE SUITE 100, ANN ARBOR MI, 48104. The company can be reached via phone at (415) 798-8589 or via email at [email protected].

This page was last updated on 1/20/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.